RxDoctor Payments Data

Leelawattie Bisnauth

Family · Yorktown, VANPI 1912583337

Payments from drug & device makers

$2,361in general payments, 2019–2025

Across 100 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$412
  • Lilly USA, LLC$403
  • Amgen$310
  • Astellas Pharma US Inc$222
  • Pfizer$187
  • GSK$154
  • plus $673 from 13 others

What the payments were for

  • Food & beverage$2,27196%
  • Education$904%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,361 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$76,358
Medicare patients
247
Services billed
1,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate31$31,501
OzempicSemaglutide29$25,570
XareltoRivaroxaban12$18,557
EliquisApixaban25$14,520
JardianceEmpagliflozin13$10,809
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$5,047
VascepaIcosapent Ethyl12$4,185
Albuterol Sulfate HfaAlbuterol Sulfate54$1,766
Atorvastatin Calcium167$1,208
Metoprolol Succinate66$853
Ultra-Fine Short Pen NeedlePen Needle, Diabetic14$800
Gabapentin100$656
Losartan Potassium83$633
Ezetimibe20$621
Rosuvastatin Calcium59$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$37$31,50131 claims
Novo NordiskOzempic$412$25,57029 claims
PfizerEliquis$187$14,52025 claims
Boehringer IngelheimJardiance$32$10,80913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$53578 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Yorktown

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →